PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
- Conditions
- Mycosis Fungoides/Sezary SyndromeLymphoma, T-Cell, Cutaneous
- Interventions
- Registration Number
- NCT03357224
- Brief Summary
Trial assessing atezolizumab (anti-PD-L1) as treatment option for patients with mycosis fungoides/sezary syndrome having progressed under or after previous therapy
For this study, we invite patients suffering from mycosis fungoides and Sézary syndrome who have progressed after initial therapy or have failed to respond to previous therapy.
Mycosis fungoides and Sézary syndrome are cancers in which lymphocytes\* become malignant (cancerous) and affect the skin. In mycosis fungoides, the disease is generally limited to the skin, and people develop flat or raised areas on their skin where the lymphocytes have accumulated. Sometimes even larger aggregations of lymphocytes occur in the skin or lymph nodes, resulting in tumors. In Sézary syndrome, the skin is often reddened or itchy, and some abnormal lymphocytes circulate in the blood.
\* Lymphocytes are a type of immune cells that is made in the bone marrow and is found in the blood. Lymphocytes have a number of roles in the immune system, including the production of antibodies and other substances that fight infections and other diseases.
In standard practice, the disease will be treated with conventional chemotherapy that unfortunately has a limited lasting benefit. In this study, we want to see if a new treatment option can optimize and improve response and make benefit last as long as possible. This new treatment option is immunotherapy, using atezolizumab (Tecentriq).
Immunotherapy is a cancer treatment that uses antibodies made in the laboratory from a single type of immune system cell. These antibodies can identify substances on cancer cells or normal cells that may help cancer cell grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Atezolizumab blocks a protein called PD-L1 (programmed death-ligand 1) from binding to its receptor found on the surface of lymphocytes. It helps to restore the immune activity of the body against the cancer.
Atezolizumab is already used to treat adults with a cancer that affects the bladder and the urinary system, called urothelial carcinoma, and a cancer that affects the lungs, called non-small cell lung cancer.
In this trial, patients will receive atezolizumab for one year unless the tumor starts growing again or this is not considered suitable for them anymore or they wish to stop the treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 26
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Experimental: Atezolizumab Atezolizumab The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
- Primary Outcome Measures
Name Time Method Best overall response (CR+PR) rate (EORTC-ISCL-USCLC criteria) Up to maximum 1 year starting from patient registration Overall response rate is defined as the proportion of patients with global response score equal to CR or PR
- Secondary Outcome Measures
Name Time Method Progression free survival (EORTC-International Society of Cutaneous Lymphoma (ISCL)-United States Cutaneous Lymphoma Consortium (USCLC) criteria) 6 months as of Last Patient In (LPI) From registration to progression
Overall survival (OS) 5 years as of LPI based on the median overall survival Registration till the date of death from any cause
Duration of response 6 months as of LPI From registration to progression
Time to response (CR/PR) 6 months as of LPI From registration to progression
Time to next systemic treatment 8 months as of LPI Time from the end of the current atezolizumab treatment until the time the next systemic treatment is recorded.
Trial Locations
- Locations (2)
Hospital Universitario 12 De Octubre
🇪🇸Madrid, Spain
UniversitaetsSpital Zurich - Division of Dermatology
🇨🇭Zürich, Switzerland